The Korea Biomedical Review reports that South Korean company, Sam Chun Dang Pharm Co Ltd (SCD), has entered an exclusive distribution agreement with an unnamed distributor to supply its Eylea® (aflibercept) biosimilar in the UK, Belgium, the Netherlands, Norway, Portugal, Sweden, Greece, Ireland and Finland. SCD attributes the deal to it being the first to apply for European Medicines Agency approval for an aflibercept biosimilar pre-filled syringe.
SCD’s biosimilar to Regeneron’s Eylea®, SCD411, was also the subject of an exclusive distribution agreement reported in November 2023, between SCD and an unnamed distributor, for supply to Austria, Germany, Italy, Spain and Switzerland. In North America, SCD has licensed SCD411 to Apotex for the Canadian market.